# A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

> **NCT02178358** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 132 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** LY2157299
- **DRUG:** Sorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02178358
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-08
- **Primary completion:** 2017-06-30
- **Final completion:** 2021-02-18
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2022-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178358, "A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02178358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*